Сравнение

Enfuvirtid vs. Pasireotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

159519-65-0

396091-73-9

Молекулярная масса

4491.88 g/mol

1047.21 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Enfuvirtid

Enfuvirtide binds the first heptad-repeat region (HR1) of the gp41 subunit of the HIV envelope protein. This prevents the conformational change required for fusion of the viral and cell membranes — the virus cannot enter the cell.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Enfuvirtid	Pasireotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Enfuvirtid and Pasireotid?: Enfuvirtid is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Enfuvirtid or Pasireotid?: The highest available evidence level is "РКИ на людях" for Enfuvirtid and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Enfuvirtid and Pasireotid in Germany and the United States?: Германия: Enfuvirtid — Рецептурный, Pasireotid — Рецептурный. США: Enfuvirtid — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Enfuvirtid

Pasireotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Enfuvirtid and Pasireotid?

Enfuvirtid is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Enfuvirtid: Enfuvirtide is a synthetic 36-amino-acid peptide and the first HIV-1 fusion inhibitor. It binds the HR1 region of the viral envelope protein gp41, blocking viral entry into the cell. Approved for treatment-experienced HIV patients. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Enfuvirtid or Pasireotid?

The highest available evidence level is "РКИ на людях" for Enfuvirtid and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Enfuvirtid and Pasireotid in Germany and the United States?

Германия: Enfuvirtid — Рецептурный, Pasireotid — Рецептурный. США: Enfuvirtid — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.